Grandview Asset Management’s AstraZeneca AZN Stock Holding History

Grandview Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-80	Closed	-$8K	–	135
2021 Q1	$8K	Buy	+80	New	+$8.04K	﹤0.01%	346

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Grandview Asset Management's AZN Position: Q2 2021 in Review

Grandview Asset Management sold out of AstraZeneca (AZN) in Q2 2021, closing a stake of 80 shares — an estimated $8K sold.

Grandview Asset Management first reported a position in AZN in Q1 2021 and held it in 1 quarter. The position peaked at $8K in Q1 2021. 768 funds tracked by Wall St. Rank hold AZN as of Q2 2021.

Grandview Asset Management reported no remaining AstraZeneca position as of Q2 2021 after selling out during the quarter.
Grandview Asset Management sold 80 AstraZeneca shares in Q2 2021, an estimated $8K.
Grandview Asset Management first reported a position in AstraZeneca in Q1 2021 and held it in 1 quarter.
Grandview Asset Management's AstraZeneca position peaked at $8K in Q1 2021.
768 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2021.

Based on Grandview Asset Management's 13F filing for Q2 2021, filed 21 Jul 2021.